Deutsche Bank increased its price target for YouGov PLC to 400p from 350p following the company's 2026 financial results, maintaining a 'buy' rating. The bank highlighted strong cost control but noted uncertainty in revenue growth due to AI changes and upcoming CEO transition. Despite a slight cut in earnings forecasts, Deutsche Bank remains optimistic about YouGov's valuation, business stabilization, and AI-driven growth potential. The outlook depends on leadership changes and the future of YouGov Shopper business.
YouGov's valuation and cost control are noted alongside Pluang's Technology sector market snapshot as of Oct 19, 2026 20:51 WIB: Out of 150 US tech stocks, 106 rose and 39 fell. Among notable movers, Entegris Inc (ENTG) gained 5.12% to USD 145.84 with a typical hold time of 41 days, Aehr Test Systems (AEHR) rose 4.92% to USD 63.58 with a 16-day hold, and Marvell Technology Inc (MRVL) increased 4.70% to USD 238.53 with a 43-day hold. This contrasts the broad positive momentum in the sector.
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
